Search clinical trials for: DVS-233 SR (desvenlafaxine sustained release )

Total 68 results

Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder

Major Depressive Disorder
Pfizer

Completed

Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)

Depression - Major Depressive Disorder

Belgium
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause

Hot Flashes | Menopause | Sleep Disorders
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder

Depressive Disorder | Depression | Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

Diabetic Neuropathy, Painful
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause

Vasomotor Symptoms

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women

Vasomotor Symptoms
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

Menopause | Vasomotor System

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)

Depressive Disorder, Major

United States
Pfizer

Completed

Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)

Major Depressive Disorder

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder

Depressive Disorder, Major Depressive Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

Depression | Major Depressive Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

Major Depressive Disorder

United States, Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects

Healthy

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women

Depressive Disorder | Depression | Depressive Disorder, Major

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

Depressive Disorder | Depression | Depressive Disorder, Major

Colombia, Mexico, United States, Peru, Chile, Argentina
Meda Pharmaceuticals

Completed

A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back

Lower Back Pain

United States
LG Life Sciences

Completed

Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)

Growth Hormone Deficiency
Pfizer

Completed

Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

Major Depressive Disorder

Canada, United States, Colombia, Croatia, Estonia, Finland, Poland, France, Slovakia, Chile, Latvia, Lithuania, Romania, South Africa
Wyeth is now a wholly owned subsidiary of Pfizer
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

Major Depressive Disorder

United States
United Therapeutics

Completed

A Pharmacokinetic Substudy of the TDE-PH-304 Protocol

Pulmonary Arterial Hypertension

United States
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Pfizer

Completed

Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)

Major Depressive Disorder
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

Depressive Disorder, Major

United States
Pfizer

Completed

Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Germany, Estonia, Finland, Former Serbia and Montenegro, France, Latvia, Lithuania, Poland, Slovakia, South Africa
Jiangsu Province Nanjing Brain Hospital

Recruiting

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder

Anhedonia

China
Ochsner Health System
United Therapeutics

Completed

Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure

Critical Limb Ischemia

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder

Major Depressive Disorder

China
University of Florida
ALS Association

Active, not recruiting

Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD

Frontotemporal Dementia | C9orf72 Amyotrophic Lateral Sclerosis (ALS)

United States
United Therapeutics

Completed

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

Pulmonary Arterial Hypertension

United States
Pfizer

Completed

Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women

Vasomotor Symptoms

Canada, United States
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia

Fibromyalgia

United States
Pfizer

Completed

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

Pharmacokinetics | Cytochrome P-450 CYP2D6 | CYP3A4 Protein, Human

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome

Fibromyalgia

United States
Pfizer

Completed

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Major Depressive Disorder

United States, Chile, Mexico
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

Major Depressive Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

Depressive Disorder, Major
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study of Desvenlafaxine in Treating Major Depressive Disorder.

Major Depressive Disorder

China
Pfizer

Completed

The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms

Vasomotor Symptoms

Canada, United States
AstraZeneca

Completed

SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia

Schizophrenic Disorder

Bulgaria, Russian Federation, Romania, South Africa, Greece, Philippines, India, Indonesia
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway

Diabetic Neuropathies | Vasomotor Symptoms | Fibromyalgia | Depressive Disorder, Major
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia (EASOPSRTFP)

Postherpetic Neuralgia

China
Mansoura University

Completed

Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute

Urinary Incontinence | Urinary Bladder Cancer | Incontinence

Egypt

3

Subscribe